MedWatch

Demant closes Q2 ahead of guidance, upgrades both revenue and earnings

The Danish hearing aid supplier exits this year's second quarter beating prior guidance and now upgrades its full-year financial outlook – both for organic growth and operating earnings.

Demants presents its Q2 interim report Thursday morning. | Photo: Jens Dresling/Politiken/Ritzau Scanpix

Hearing aid company Demant's business has been booming in the first half of 2021 – so much so that the group now books an upward adjustment of its full-year guidance.

Demant now banks on organic growth of 26-30 percent against the prior spread of 24-28 percent, also dialing up on its expectations for annual earnings before interest and taxes from DKK 3-3.3bn (USD 470-520m) to DKK 3.15-3.45bn, the company informs in its H1 interim report.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs